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T13th International Congress on Infectious Diseases Abstracts
Infection control: 1) Single room or cohort, 2) bar-
rier precautions, 3) avoid rectal thermometers, 4) chlorine
1000 ppm room cleaning, 5) early detection, 6) BioQuell -
experimental and 7) outbreak - control antibiotics and soap
for hand hygiene.
Prevention of relapses: Avoid ‘‘bad’’ Abx and antiperi-
staltics; role of probiotics and gastric pH control - unknown.
doi:10.1016/j.ijid.2008.05.100
34.004
Managing CDAD: Current and Upcoming Approaches
J. Pepin
U of Sherbrooke, Sherbrooke, Canada
The epidemiology, clinical severity and case-fatality ratio
of Clostridium difﬁcile infection (CDI) changed dramati-
cally with the emergence of a toxin hyperproducing strain
(BI/NAP1/027) in North America and Europe since 2000.
These changes have stimulated the quest for novel thera-
peutic approaches, and a re-examination of the comparative
efﬁcacy of metronidazole versus oral vancomycin. Unfortu-
nately, tolevamer, the only novel treatment evaluated so
far in phase 3 trials, has proven inferior to comparators,
and metronidazole and vancomycin remain the two most
commonly used drugs. The major advantage of metron-
idazole is its low price. The major advantage of orally
administered vancomycin lies in its more favorable phar-
macokinetics. Facilitating vancomycin-resistant enterococci
colonization/infection is a potential drawback of both drugs.
The randomized controlled trials published so far used
intermediate outcomes rather than outcomes that now
preoccupy clinicians: the frequency of complications or
recurrences. Pending the development of a prospectively
validated scoring system, the IDSA/SHEA expert committee
will deﬁne severe CDI as any patient with a leukocyto-
sis ≥15000/mm3 or a creatinine increased by ≥50% from
baseline. For patients with mild-to moderate CDI (leuko-
cytosis <15000/mm3 and creatinine <1.5 X baseline), there
is no evidence that vancomycin is superior to metronida-
zole (even for intermediate outcomes), and metronidazole
should be preferred. For patients with severe CDI not
infected with BI/NAP1/027, there is reasonable evidence
that the better pharmacokinetics of vancomycin translate
into a lower probability of complications. For those infected
with BI/NAP1/027, the superiority of vancomycin remains to
be proven. About one fourth of patients treated with either
metronidazole or vancomycin will experience at least one
recurrence. There is now some evidence that the more com-
mon post-metronidazole recurrences documented recently
in some centers may have corresponded to re-infections
among patients who remained exposed in the hospital envi-
ronment.
doi:10.1016/j.ijid.2008.05.101
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ervical Cancer Vaccination: The Need for Strong and
ustained Protection (invited)
5.001
PV Types 16, 18, 45 and 31: The Most Important
ncogenic HPV Types Worldwide
.X. Bosch
Catalan Institute of Oncology IDIBELL, Barcelona, Spain
PV infections are the most common sexually transmitted
nfections. HPV types differ in transmission capacity, vir-
lence and in their ability to induce cancer. Over 90% of
PV-attributable cancers in women are cervical cancer. Most
ancers of the uterine cervix are squamous cell carcinomas,
hile adenocarcinoma represents 10-12% of the global cer-
ical cancer burden (in some countries of Europe and North
merica it amounts to over 20% of all invasive cervical can-
er).
On worldwide estimates, HPV-16 is consistently the most
ommon type (60%) in cervical cancer, followed by HPV-
8, -45 and -31. These four types combined account for
pproximately 80% of squamous cell carcinomas and 90% of
denocarcinomas. Some variability in the ranking thereafter
as been described.
Infections with HPV-16, -18, or -45 are associated with a
igher risk for progression to cancer. The prognosis of HPV-16
nd -18 is now being established by cohort studies with 10+
ears of follow-up. The probability and time to progression
o HSIL among HPV-16 and/or HPV-18 positive women with
ormal cytology is signiﬁcantly higher than for any other
f the high-risk HPV types, although the estimates for each
ndividual type other than HPV-16 and -18 have not been
rmly established.
Adenocarcinoma is not detected effectively by cervical
creening and is increasing in incidence in Europe and North
merica. It is associated with higher recurrence rates and
oor outcomes. HPV-18 and -45 account for more than 40%
f adenocarcinomas.
Among other HPV positive cancer cases, HPV-16 is the
ominant type. HPV-18 and-45 are the next most common
ypes, although the relative role of the remaining HPV types
s still to be determined.
In summary, on a worldwide scale, prevention of cervi-
al and other genital cancers would greatly beneﬁt from
accination focused on HPV-16 and -18.
oi:10.1016/j.ijid.2008.05.102
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he Value of New Adjuvant Technology
. Zepp1,∗, N. Garc¸on2,∗
Children’s Hospital, Johannes Gutenberg, Mainz, Germany
GSK, Rixensart, Belgium
he development of safe and efﬁcacious vaccines against
athogens like malaria, HIV and TB and the induction of
rotective immune responses in populations with impaired
mmunity such as the elderly remain major challenges. The
rowing understanding of the role of the innate immune sys-
em in the initial triggering of speciﬁc, adaptive immune
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esponses has stimulated new vaccine-concepts, especially
n the ﬁeld of adjuvant development.
Over the past two decades GSK Biologicals has developed
n Adjuvant Systems (AS) platform. AS families are formu-
ated with selected antigen(s) and are designed to enhance
he immune response to the targeted pathogen for the tar-
et population. Extensive preclinical and clinical testing
as lead to the development of AS-based candidate vac-
ines for malaria (RTS,S), HSV, H5N1 prepandemic inﬂuenza,
nd licensed vaccines for HBV and cervical cancer preven-
ion (HPV) formulated with novel adjuvant technology.The
SK proprietary novel Adjuvant System AS04 (aluminium
ydroxide combined with the immunostimulatory molecule,
-0-desacyl-4′-monophosphoryl lipid A) has been combined
ith HPV 16 and -18 virus-like-particles to tailor the immune
esponse optimally against a virus that typically hides from
he immune system.
The immune response induced by the AS04-adjuvanted
ervical cancer vaccine has been assessed in pre-clinical and
linical studies. In clinical studies, GSK’s both HPV-16 and -
8 L1-VLPs when adjuvanted with AS04, induced a stronger
nd more sustained immune response for at least 4 years
fter the ﬁrst dose, than when adjuvanted with aluminium
ydroxide alone. In addition, AS04 allowed for higher and
ustained concentrations of neutralising antibodies, as well
s higher frequencies of memory B-cells.1
New vaccine technologies have opened the door to vac-
ination against diseases that were not preventable before.
SK has formulated its cervical cancer vaccine with AS04 to
ddress the need for long term protection against oncogenic
PV, a virus that typically hides from the immune system and
or which the disease remain silent for years, if not detected
y classical screening methods such as PAP smears.
eference
1. Giannini SL, et al. Vaccine 2006;24:5937—49.
oi:10.1016/j.ijid.2008.05.103
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mplementation of Cervical Cancer Vaccination. Reaching
irls and Women: Challenges and Opportunities
-K. Tay
Singapore General Hospital, Singapore, Singapore
ervical cancer is the most common cancer in women in
any parts of Asia. Indeed, 54% of the world’s cervical can-
er burden is in Asia. Although cervical cancer screening
ith Pap smears has been effective, most Asian countries
on’t have the resources to implement a comprehensive
creening programme. Implementation of vaccination pro-
ides a realistic approach to improve cervical cancer control
n these countries.
In Asia, successful implementation of cervical cancer vac-
ination can present more of a challenge than it does on
ther continents. Experience following the introduction of
accination against common childhood infections highlights
everal practical issues, particularly concerning vaccination
olicy, ﬁnancing and system capacity for vaccine delivery
p
o
o
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nd inoculation. While the efﬁcacy and tolerability of anti-
PV-16/18 vaccines are well established, policymakers in
any Asian countries aren’t ready to formulate a national
olicy.
Implementation of anti-HPV-16/18 vaccination in Asia
s likely to start with opportunistic vaccination of individ-
al women. Physicians will introduce the vaccine to their
atients seeking cervical screening or attending consulta-
ions for other reasons. Caretakers will also discuss the
eneﬁts of vaccination for their adolescent daughters with
hese patients. In some Asian regions, opportunistic cytol-
gy screening has reached a high level of penetration and
ervical cancer incidence is declining. Opportunistic anti-
PV-16/18 vaccination may gain momentum in a similar
anner to cytology screening. Once sufﬁcient demand from
ndividuals for anti-HPV-16/18 vaccines is reached, poli-
ymakers are likely to adopt national policies for mass
accination of targeted populations.
An important ﬁrst step in implementing anti-HPV-16/18
accines in Asia should be to focus on heightening awareness
f the need for effective strategies for cervical cancer pre-
ention and the role of opportunistic vaccination among the
eneral public and primary healthcare workers. In a two-
ronged approach, a private-public partnership between
ndustry and global charity organisations on competitive
nancing will further catalyse the wider acceptance of
ervical cancer vaccination.
oi:10.1016/j.ijid.2008.05.104
acrolides - Yesterday, Today and Tomorrow (invited)
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TI: Treatment Challenges
. Esposito1,∗, B. Barsic2
Institute of Pediatrics, University of Milan, Fondazione
RCCS ‘Ospedale Maggiore Policlinico, Mangiagalli e Regina
lena’, Milan, Italy
Hospital for Infectious Diseases, School of Medicine,
agreb, Croatia
evere community-acquired pneumonia (CAP) treated in
ntensive care units (ICU) represents a great therapeutic
hallenge. There is growing evidence on the importance of
typical pathogens and combined infections as causes of
evere CAP. Data from our single-center study show that
egionella and atypical pathogens are associated with over
0% of CAP. That is why combined ceftriaxone and par-
nteral azithromycin therapy became a standard treatment
n our ICU. This is congruent with a majority of contempo-
ary treatment guidelines which recognized the importance
f a combined treatment of severe CAP. Evidences on the
ole of atypical pathogens, particularly C. pneumoniae,
n the etiology of nosocomial pneumonia (NP), including
entilator-associated pneumoniae (VAP), are also emerg-
ng. These pathogens are not so well recognized as possible
athogens and considered in present treatment guidelines
f NP. Further surveillance is needed which might change
ur initial therapeutic approach in patients with NP.
In pediatric patients, Mycoplasma pneumoniae and
hlamydophila pneumoniae seem to play a more signiﬁcant
